Clinical trials: SARS-COV2 Virus
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability…
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Trial name
- NCT04754594
- Testing
- BNT162b2
- Where
- 90 sites in United States, Brazil and 3 more
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2, COVID-19
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
The purpose of this research is to gather information to answer questions about the Coronavirus Disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- EPIC3 (NCT05764083)
- Where
- United States
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion
This is the first-in-human phase 1/2a trial of the intravenous administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631666
- Testing
- DZIF-10c
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Critical Confirmed Coronavirus Disease (COVID)-19
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
- Trial name
- NCT04380961
- Testing
- Sirukumab, Standard of Care (SOC)
- Where
- 16 sites in United States
- Volunteers
- 212 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Sars-CoV2
Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic
SARS-CoV-2 induced by COVID 19, involved the hospitalization of 101,932 patients in France, including 4,007 in intensive care (source: Santé Publique France).
- Trial name
- COVID-PRONE (NCT04438941)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Coronavirus Infection
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia
In early December 2019, cases of pneumonia of unknown origin were identified in Wuhan, China. The causative virus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- COP-COVID-19 (NCT04358783)
- Testing
- Plasma, Best Available Therapy
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Novel Coronavirus Infectious Disease (COVID-19)
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global.
- Trial name
- NCT04286503
- Testing
- Carrimycin, lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate, basic treatment
- Volunteers
- 520 people
- Sponsor
- Beijing YouAn Hospital
Covid19
Antigen Rapid Test Screening to Prevent SARS-CoV-2 Transmission (COVID-19) at Mass Gathering Events.
To investigate the impact of rapid antigen testing for Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), the investigators plan to conduct a large trial to assess the impact of using rapid tests to screen people…
- Trial name
- NCT04898127
- Testing
- SARS-CoV-2 antigen rapid test
- Sponsor
- Norwegian Institute of Public Health
Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS
A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.
- Trial name
- NCT04615429
- Testing
- Mesenchymal stromal cells
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cristina Avendaño Solá
COVID-19, Thrombosis Embolism
The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19
Thromboembolisms (TEs) in patients with critical COVID-19 has been reported to be three times higher than for other critically ill patients. Immunothrombosis has been proposed as a plausible mechanism for COVID-19 coagulopathy.
- Conditions
- COVID-19, Thrombosis Embolism, Bleeding
- Trial name
- NCT05195242
- Testing
- Dexamethasone
- Where
- Sweden
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Long COVID, Post-COVID-19 Condition
Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients
Mitochondria are structures inside cells that are responsible for producing energy from nutrients through a series of steps, using oxygen.
- Trial name
- MitoLoCo (NCT07134673)
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Patients With Cancer, Vaccine Reaction
Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection.
- Conditions
- Patients With Cancer, Vaccine Reaction, COVID-19
- Trial name
- NCT05273541
- Testing
- Coronavirus vaccination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing 302 Hospital
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and…
- Trial name
- VACOVAJI (NCT05547451)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital
COVID-19 Prevention
Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray
The purpose of this study is to test the safety of multiple doses of a Q-GRFT nasal spray in healthy volunteers. This Q-GRFT nasal spray is "investigational and not approved by the FDA for general use" and is being developed to…
- Trial name
- NCT05437029
- Testing
- Q-Griffithsin 3.0, Q-Griffithsin 6.0
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kenneth Palmer
The Gold Standard for Current SARS CoV2 Detection is RT-PCR
Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.
All patients included in this search will be on anonymized file: Symptomatic patients consulting for suspicion of COVID 19 with indication to a screening (RT-PCR, Scanner) according to the criteria of the Ministry of Health.
- Trial name
- NCT04339686
- Testing
- Thoracic CT Scan
- Where
- France
- Volunteers
- 56,000 people
- Sponsor
- Poitiers University Hospital
Covid19
Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on…
- Trial name
- NCT04608305
- Testing
- IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime)
- Where
- 8 sites in Israel
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Israel Institute for Biological Research (IIBR)
Coronavirus
Patient Preference Trial for COVID-19 (PPT-COVID)
To date no treatment has proven its effectiveness in the caring of patients infected with type 2 Coronavirus. The Centre Hospitalier Princesse Grace (CHPG) has decided to only propose randomized double-blind placebo-controlled…
- Trial name
- PPT-COVID (NCT04418193)
- Where
- Monaco
- Sponsor
- Centre Hospitalier Princesse Grace
Covid19, SARS-CoV Infection
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
The main objective of this cohort is to characterize COVID-19 patients hospitalized in infectious disease department. The collection of clinical and biological data from start of hospitalization to long-term follow up will…
- Trial name
- NCT04779021
- Testing
- Hospitalisation for SARS-COV2 infection
- Where
- 2 sites in France
- Volunteers
- 1,300 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Covid19
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- NCT04564716
- Testing
- Gam-COVID-Vac
- Where
- 8 sites in Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.